Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPK-006
- Development stage
- Preclinical
- Lead developer
- EPIK Biosciences
- Modality
- Small Molecules
01
Overview
EPK-006 is a preclinical-stage drug candidate being developed by EPIK Biosciences. It is part of the company's pipeline of synergistic combination medicines that leverage either ketamine or dextromethorphan (DXM) as core active ingredients, combined with other FDA-approved, non-Schedule I compounds. Rooted in NMDA receptor modulation, the program is designed to target central nervous system (CNS) disorders, including mental health conditions (such as depression, anxiety, and PTSD), severe chronic pain, and substance use disorders. EPIK Biosciences is utilizing a 505(b)(2) regulatory pathway to advance these combination therapies, aiming to improve efficacy, durability, and safety while enabling convenient, at-home administration.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on EPK-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPK-006.